Differences in incidence and co‐occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33

• Published in: International journal of cancer Vol. 128; no. 5; pp. 1114 - 1119
• Main Authors: Merikukka, Marko, Kaasila, Marjo, Namujju, Proscovia B., Palmroth, Johanna, Kirnbauer, Reinhard, Paavonen, Jorma, Surcel, Heljä‐Marja, Lehtinen, Matti
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2011; Wiley-Blackwell; Wiley Subscription Services, Inc
• Subjects: Alphapapillomavirus - classification; Alphapapillomavirus - immunology; Antibodies; Antibodies, Viral - blood; Biological and medical sciences; Cancer; Cohort Studies; competition; Competitive advantage; Female; Finland; Human papillomavirus; Human papillomavirus 16; Human papillomavirus 18; Humans; Immunization; incidence rate ratio; Infectious diseases; Medical research; Medical sciences; population; Pregnancy; serology; Tumors; Vaccination; Viral diseases; Viral Vaccines - administration & dosage; Europe; Finland; Competition; Human; Vaccination; Serology; Vaccine; incidence rate ratio; Papovaviridae; Epidemiology; Incidence; population; Infection; Papillomavirus; Virus; Mass; Prevention; Human papillomavirus; Cancerology; Viral disease
• ISSN: 0020-7136; 1097-0215; 1097-0215
• DOI: 10.1002/ijc.25675

To understand likelihood of type replacement after vaccination against the high‐risk human papillomavirus (HPV) types, we evaluated competition of the seven most common genital HPV types in a population sample of unvaccinated, fertile‐aged Finnish women. First trimester sera from two consecutive pregnancies were retrieved from 3,183 Finnish women (mean age, 23.1 years) of whom 42.3% had antibodies to at least one HPV type (6/11/16/18/31/33/45) at the baseline. Antibody positivity to more than one HPV types by the second pregnancy was common among the baseline HPV seropositives. However, compared to baseline HPV‐seronegative women, significantly increased incidence rate ratios (IRRs), indicating an increased risk to seroconvert for another HPV type, were consistently noted only for HPV33 among baseline HPV16 or HPV18 antibody (ab)‐positive women: HPV16ab only → 16&33ab IRR 2.9 [95% confidence interval (CI) 1.6–5.4] and HPV18ab only → 18&33ab IRR 2.5 (95% CI 1.1–6.0), irrespectively of the presence of antibodies to other HPV types at baseline: HPV16ab → 16&33ab IRR 3.2 (95% CI 2.0–5.2) and HPV18ab → 18&33ab IRR 3.6 (95% CI 2.1–5.9). Our findings suggest a possible competitive advantage for HPV33 over other genital HPV types in the unvaccinated population. HPV33 should be monitored for type replacement after HPV mass vaccination.